2022 in Review: After two years of IPOs, the region’s publicly traded life sciences firms hit tough times


Only two of the companies that went public since 2020 are trading above their IPO price.

Previous Commute-Worthy Spaces: Kirk Burkley on Bernstein-Burkley's office at 601 Grant St.
Next 2022 BBJ CEO Awards: Andrew Patterson, Shannon Waltchack